Catalent Appoints Two Senior Executives to Support Global Development and Clinical Services Business Growth
Catalent Pharma Solutions has announced two appointments to the management structure of its development and clinical services division, to further support its global customer needs. The move sees the creation of two new senior leadership roles to support drug development and clinical trial growth in the US, Europe and Asia.
Mr Paul Hegwood, currently VP Operations for the clinical supply services offerings will assume the new role of VP Operations for the development and clinical services division for the Americas and Asia-Pacific regions. Mr Stuart Cryer, who is currently VP Operations for the development and analytical solutions offerings, will become the new VP Operations for the development and clinical services division for Europe and the rest of world.
“These appointments are part of our strategic investment and growth strategy across our global network, especially for our fast growing clinical supply services network, which comprises eight GMP facilities and over 50 depots across all continents,” commented Scott Houlton, President and CEO, development and clinical services. “The move provides further regional customer focus, plus greater local regulatory expertise, and will facilitate faster execution to support our clients’ needs wherever they are in the world.”
Paul Hegwood was named Vice President of global operational excellence for Catalent in April 2011, following an extensive career leading multi-national teams in operations, business development and product engineering. He had previously held the position of VP of global operations for Stanadyne Corp. and has held various leadership positions at General Motors and its automotive electronics and technology company, Delphi. He holds an MBA from the University of Michigan and a BME from Kettering University. Mr Hegwood is a trained specialist in lean manufacturing and is a certified Six Sigma Green Belt.
Mr Cryer has a Bachelor of Pharmacy honors degree from Bath University and more than 25 years’ experience in the pharmaceutical industry. He has worked for a broad range of pharmaceutical organisations including Pfizer, Abbott, GSK and Aptuit. He has held roles in formulation and development, technical support and operational management.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance